Back to Oncology
Oncologyv1999Evidence-Based

Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)

Predicts survival based on clinical and laboratory data in metastatic RCC patients

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
mskcc score
—risk factors
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Score = Sum of present risk factors (0-5)

Clinical Pearls & Practice Notes

  • Use baseline factors at the start of systemic therapy
  • Always correct calcium concentration for low albumin using formula: Corrected Ca = Measured Ca + 0.8 × (4 - Albumin)
  • Originally developed for patients treated with interferon-alpha
  • The IMDC Risk Model is now preferred for patients receiving targeted therapy
  • Karnofsky Performance Status < 80% indicates inability to carry out normal activities

Evidence & Literature Citations

  1. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 Aug;17(8):2530-40. doi: 10.1200/JCO.1999.17.8.2530.
  2. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002 Jan 1;20(1):289-96. doi: 10.1200/JCO.2002.20.1.289.
  3. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004 Feb 1;22(3):454-63. doi: 10.1200/JCO.2004.06.132.

Score Interpretation Ranges

Good Risk0 – 0 pts

0 risk factors

Intermediate Risk1 – 2 pts

1-2 risk factors

High Risk3 – 5 pts

≥3 risk factors

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.